AURA · Insider Trading
Aura Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by AURA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Susan Abu-Absi | Chief Operating Officer | A | +134,513 | — |
| 2026-09-01 | Erica Kratz | Chief Reg. & Quality Officer | A | +100,885 | — |
| 2026-09-01 | Julie Person | Chief People Officer | A | +107,611 | — |
| 2026-09-01 | Janet Jill Hopkins | Chief Medical Officer | A | +58,850 | — |
| 2026-09-01 | Amy Elazzouzi | SVP, Finance & PAO | A | +23,540 | — |
| 2026-07-08 | Jeremy Bender | Director | A | +30,000 | — |
| 2026-07-01 | Conor Kilroy | See Remarks | A | +14,858 | — |
| 2026-06-16 | Anthony S Gibney | See Remarks | Sell | −12,824 | −$82.33K |
| 2026-06-15 | Antony C. Mattessich | Director | A | +15,000 | — |
| 2026-06-15 | Teresa Marie Bitetti | Director | A | +15,000 | — |
| 2026-06-15 | Sapna Srivastava | Director | A | +15,000 | — |
| 2026-06-15 | David Michael Johnson | Director | A | +15,000 | — |
| 2026-05-19 | Natalie C. Holles | See Remarks | A | +1,153,962 | — |
| 2026-05-11 | David E. Goel | 10%+ Owner | Sell | −13,845,740 | −$78.09M |
| 2026-04-16 | Conor Kilroy | See Remarks | Sell | −11,738 | −$82.40K |
| 2026-03-03 | Janet Jill Hopkins | Chief Medical Officer | A | +89,056 | — |
| 2026-03-03 | Anthony S Gibney | See Remarks | A | +71,245 | — |
| 2026-03-03 | Amy Elazzouzi | Senior Vice President, Finance | A | +44,528 | — |
| 2026-03-03 | Pinos Elisabet de los | See Remarks | A | +166,000 | — |
| 2026-03-03 | Mark Plavsic | Chief Technology Officer | A | +62,339 | — |
| 2026-03-03 | Conor Kilroy | See Remarks | A | +62,339 | — |
| 2026-02-17 | Conor Kilroy | See Remarks | Sell | −12,079 | −$61.00K |
| 2026-02-17 | Amy Elazzouzi | Senior Vice President, Finance | Sell | −8,549 | −$43.26K |
| 2026-02-17 | Pinos Elisabet de los | See Remarks | Sell | −47,648 | −$241.10K |
| 2026-02-17 | Janet Jill Hopkins | Chief Medical Officer | Sell | −20,401 | −$103.23K |
| 2026-02-17 | Mark Plavsic | Chief Technology Officer | Sell | −15,890 | −$80.24K |
| 2026-01-20 | Amy Elazzouzi | Senior Vice President, Finance | Sell | −1,581 | −$7.68K |
| 2026-01-20 | Pinos Elisabet de los | See Remarks | Sell | −16,928 | −$82.27K |
| 2025-11-17 | Janet Jill Hopkins | Chief Medical Officer | Sell | −17,109 | −$92.73K |
| 2025-10-29 | Amy Elazzouzi | Senior Vice President, Finance | Sell | −896 | −$5.69K |
| 2025-10-29 | Pinos Elisabet de los | See Remarks | Sell | −9,049 | −$57.46K |
| 2025-10-16 | Mark Plavsic | Chief Technology Officer | Sell | −12,169 | −$77.27K |
| 2025-08-18 | Amy Elazzouzi | Senior Vice President, Finance | MIXED | +5,177 | −$635 |
| 2025-06-18 | Antony C. Mattessich | Director | A | +13,000 | — |
| 2025-06-18 | Sapna Srivastava | Director | A | +13,000 | — |
| 2025-06-18 | David Michael Johnson | Director | A | +13,000 | — |
| 2025-06-04 | Anthony S Gibney | See Remarks | A | +150,000 | — |
| 2025-06-04 | Pinos Elisabet de los | See Remarks | MIXED | +1,000 | −$5.77K |
| 2025-05-20 | Anthony S Gibney | See Remarks | MIXED | +48,481 | +$237.18K |
| 2025-05-20 | David Michael Johnson | Director | Buy | +20,000 | +$98.00K |
| 2025-04-16 | Conor Kilroy | See Remarks | Sell | −7,162 | −$39.32K |
| 2025-04-16 | Amy Elazzouzi | Senior Vice President, Finance | Sell | −897 | −$4.92K |
| 2025-04-02 | Teresa Marie Bitetti | Director | A | +21,000 | — |
| 2025-02-18 | Mark Plavsic | Chief Technology Officer | Sell | −2,151 | −$16.67K |
| 2025-02-18 | Pinos Elisabet de los | See Remarks | Sell | −20,221 | −$156.80K |
| 2025-02-18 | Amy Elazzouzi | Senior Vice President, Finance | Sell | −1,404 | −$10.88K |
| 2025-02-18 | Janet Jill Hopkins | Chief Medical Officer | Sell | −2,534 | −$19.64K |
| 2025-02-04 | Amy Elazzouzi | Senior Vice President, Finance | A | +45,240 | — |
| 2025-02-04 | Pinos Elisabet de los | See Remarks | A | +194,320 | — |
| 2025-02-04 | Conor Kilroy | See Remarks | A | +90,475 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Natalie C. Holles | See Remarks | 1,153,962 | $7.13M |
| Pinos Elisabet de los | See Remarks | 703,578 | $4.35M |
| Janet Jill Hopkins | Chief Medical Officer | 380,190 | $2.35M |
| David Michael Johnson | Director | 269,167 | $1.66M |
| Anthony S Gibney | See Remarks | 265,354 | $1.64M |
| Mark Plavsic | Chief Technology Officer | 243,736 | $1.51M |
| Conor Kilroy | See Remarks | 232,693 | $1.44M |
| Amy Elazzouzi | SVP, Finance & PAO | 143,600 | $887.45K |
| Susan Abu-Absi | Chief Operating Officer | 134,513 | $831.29K |
| Julie Person | Chief People Officer | 107,611 | $665.04K |
| Erica Kratz | Chief Reg. & Quality Officer | 100,885 | $623.47K |
| Sapna Srivastava | Director | 38,500 | $237.93K |
| Antony C. Mattessich | Director | 38,500 | $237.93K |
| Teresa Marie Bitetti | Director | 36,000 | $222.48K |
| Jeremy Bender | Director | 30,000 | $185.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AURA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.